Medication-Wide Association Studies

Undiscovered side effects of drugs can have a profound effect on the health of the nation, and electronic health‐care databases offer opportunities to speed up the discovery of these side effects. We applied a “medication‐wide association study” approach that combined multivariate analysis with exploratory visualization to study four health outcomes of interest in an administrative claims database of 46 million patients and a clinical database of 11 million patients. The technique had good predictive value, but there was no threshold high enough to eliminate false‐positive findings. The visualization not only highlighted the class effects that strengthened the review of specific products but also underscored the challenges in confounding. These findings suggest that observational databases are useful for identifying potential associations that warrant further consideration but are unlikely to provide definitive evidence of causal effects.

[1]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[2]  E. Spjøtvoll,et al.  Plots of P-values to evaluate many tests simultaneously , 1982 .

[3]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[4]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[5]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[6]  S Shapiro,et al.  Confounding by indication? , 1997, Epidemiology.

[7]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[8]  Patrick C Waller,et al.  A model for the future conduct of pharmacovigilance , 2003, Pharmacoepidemiology and drug safety.

[9]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[10]  F. Arellano.  The withdrawal of rofecoxib , 2005, Pharmacoepidemiology and drug safety.

[11]  Patrick Musonda,et al.  Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.

[12]  C. Krueger.  Drug-Induced Diseases: Prevention, Detection, and Management , 2006 .

[13]  D Geffner-Sclarsky,et al.  [Hospital care for stroke patients in the Valencian Region using the basic minimum data set from the International Classification of Diseases, 9th revision, clinical modification]. , 2006, Revista de neurologia.

[14]  M. Kulldorff,et al.  Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.

[15]  Mph Dr. Syed Rizwanuddin Ahmad MD.  Adverse drug event monitoring at the food and drug administration , 2007, Journal of General Internal Medicine.

[16]  Kenneth D. Mandl,et al.  The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction , 2007, PloS one.

[17]  Cameron Rhudy,et al.  How Congress May Have Failed Consumers with the Food and Drug Administration Amendments Act of 2007 , 2008 .

[18]  Jesse A Berlin,et al.  Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.

[19]  Comparisons and Applications of Quantitative Signal Detections for Adverse Drug Reactions (ADRs): An Empirical Study Based On The Food And Drug Administration (FDA) Adverse Event Reporting System (AERS) And A Large Medical Claims Database , 2008 .

[20]  Xiaoyan Wang,et al.  Characterizing environmental and phenotypic associations using information theory and electronic health records , 2009, BMC Bioinformatics.

[21]  Heather J Whitaker,et al.  The methodology of self-controlled case series studies , 2009, Statistical methods in medical research.

[22]  Ricardo J Komotar,et al.  Genomewide Association Studies of Stroke. , 2009, Neurosurgery.

[23]  Marylyn D. Ritchie,et al.  PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations , 2010, Bioinform..

[24]  David Madigan,et al.  Bayesian Methods in Pharmacovigilance , 2010 .

[25]  D. Blumenthal,et al.  The "meaningful use" regulation for electronic health records. , 2010, The New England journal of medicine.

[26]  J. Overhage,et al.  Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.

[27]  D. Blumenthal,et al.  Achieving a Nationwide Learning Health System , 2010, Science Translational Medicine.

[28]  Cédrick Fairon,et al.  Annotation analysis for testing drug safety signals using unstructured clinical notes , 2012, J. Biomed. Semant..

[29]  Thomas P. Gross,et al.  The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.

[30]  Russ B. Altman,et al.  A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports , 2012, J. Am. Medical Informatics Assoc..

[31]  P Ryan,et al.  Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.

[32]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[33]  D. Madigan,et al.  Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.

[34]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[35]  Martijn J. Schuemie,et al.  Using Electronic Health Care Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods , 2012, Medical care.

[36]  N. Shah,et al.  Pharmacovigilance Using Clinical Notes , 2013, Clinical pharmacology and therapeutics.

[37]  N. Shah,et al.  Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.